Peptides on the Doping List: A 2026 WADA Reference

Nearly every peptide sold for recovery, muscle or anti-aging is banned for tested athletes, in and out of competition. On the 2026 WADA Prohibited List, BPC-157 falls under S0, while TB-500, IGF-1 and the growth hormone secretagogues (ipamorelin, CJC-1295, hexarelin, MK-677) fall under S2; semaglutide and tirzepatide are not banned but are on WADA's 2026 Monitoring Program. In the United States, USADA enforces the WADA Prohibited List in Olympic and Paralympic sport, and the NCAA bans the same class of peptide hormones and growth factors, naming BPC-157, TB-500 and MK-677. This guide maps which peptides are on the list, where each sits in WADA's classification, and what that means for an athlete who wants a clean career. For Norwegian readers, there is a Norwegian version for Antidoping Norge.

Key takeaways#

• The 2026 WADA Prohibited List, in force since 1 January 2026, places most peptides in categories S0, S2, or S4, all banned in and out of competition.
• BPC-157 has been on the list since January 2022 under S0 (Non-Approved Substances), and USADA says a Therapeutic Use Exemption for it is unlikely to be approved.
• TB-500 (thymosin beta-4) is explicitly prohibited under S2.3 growth factors, alongside IGF-1 and mechano growth factors; myostatin inhibitors sit in S4.3, and MOTS-c is named in S4.4 (metabolic modulators).
• All growth hormone secretagogues (GHRP-2, GHRP-6, hexarelin, ipamorelin, CJC-1295, sermorelin, tesamorelin) fall under S2.2 and trigger 2 to 4 year sanctions.
• Semaglutide and tirzepatide remain on WADA's 2026 Monitoring Program, not the Prohibited List, but use is being tracked in and out of competition.

The WADA framework places peptides across three categories#

Understanding which "S" code applies to a given peptide matters because the category determines whether a Therapeutic Use Exemption is even possible. WADA's prohibited substances fall into categories including S0 non-approved substances, S1 anabolic agents, S2 peptide hormones, growth factors, related substances, and mimetics, S3 beta-2 agonists, S4 hormone and metabolic modulators, and S5 diuretics and masking agents . Peptides cluster in three of these.

WADA organises prohibited substances into lettered categories with peptides distributed across three sections based on mechanism and regulatory status. S0 covers non-approved substances, meaning compounds without regulatory authorisation for human therapeutic use in any jurisdiction. S2 includes peptide hormones, growth factors, and related substances, which is where most growth hormone secretagogues and myostatin inhibitors land. S4 captures hormone and metabolic modulators, including myostatin inhibitors (S4.3), insulins (S4.4.2) and the mitochondrial peptide MOTS-c, which the 2026 List names as an AMPK activator under S4.4.1 (WADA). GLP-1 receptor agonists are not in S4 or anywhere else on the Prohibited List; they are on the Monitoring Program (below).

National anti-doping agencies adopt this list as written. In the United States that agency is USADA, which tests athletes in Olympic and Paralympic sport and enforces the WADA list without a separate national version; Antidoping Norge and other national agencies do the same. If WADA prohibits a substance, it is prohibited wherever the Code applies.

WADA routing decision tree for peptides

BPC-157 sits in S0, where a TUE is unlikely#

BPC-157 is the peptide most often misunderstood by athletes who later face sanctions. WADA has named it on the Prohibited List since 1 January 2022, under Section S0, Non-Approved Substances: any pharmacological substance with no current approval by a governmental health authority for human therapeutic use, and not covered by another section. The 2026 List still names it there.

The implications are unforgiving. S0 is prohibited at all times, so a positive out-of-competition test in the off-season carries the same consequence as one on competition day. A first violation typically brings a ban of two to four years, depending on findings about intent.

An exemption is not a realistic route. USADA's guidance says a Therapeutic Use Exemption for BPC-157 "is unlikely" to be approved because permitted alternatives exist, although each application is considered case by case, and notes that it is not approved for human clinical use by the FDA or any other health authority. Detection is well documented: a validated weak cation exchange solid phase extraction method detects BPC-157 in urine down to 0.1 ng/mL, and BPC-157 was stable in stored urine samples for at least four days (Cox et al., 2017); a later method lowered the limit of detection to 0.01 ng/mL and added its metabolites (Tian et al., 2023). No human excretion study has published a fixed detection window.

A note on the US compounding news. In April 2026 the FDA removed BPC-157 and eleven other peptides from its Category 2 list of substances flagged for safety concerns, and in July 2026 an FDA advisory committee voted to recommend BPC-157 for the 503A compounding list. On October 28, 2026 HHS signed a draft enforcement-discretion policy, published in the Federal Register on October 30 (91 FR 68526): HHS does not intend to take enforcement action against state-licensed 503A pharmacies and licensed physicians that compound BPC-157 acetate (subcutaneous, intramuscular, oral or topical), TB-500 acetate (injection), Epitalon acetate, Semax free base (intranasal), KPV acetate or MOTS-c acetate on a valid patient-specific prescription, as a single active ingredient, under further conditions. None of this is FDA approval, none of these peptides is on the 503A bulks list (current status on the regulatory tracker), and none of it changes WADA status. A prescription for compounded BPC-157 is not a Therapeutic Use Exemption: the S0 ban is intact.

TB-500 and the S2 growth factor subsection capture recovery peptides#

The S2 category is where injury-recovery peptides live. The same US compounding policy covers TB-500 acetate, and it does not change TB-500's S2 status. This subcategory bans peptide growth factors. Thymosin beta-4 and derivatives such as TB-500 are explicitly prohibited . WADA's wording is structured to capture analogues even where they are not named individually: Thymosin-β4 and its derivatives such as TB-500 are listed, alongside other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching .

This catch-all language matters. Mechano growth factor (MGF), IGF-1 and its analogues, fibroblast growth factors, and vascular endothelial growth factor all fall inside the same regulatory net. The BSCG summary of S2 puts it bluntly: many peptides, including synthetic analogues related to growth hormone and erythropoiesis stimulation, are prohibited by WADA regardless of dosage or source. Peptides advertised as research chemicals generally fall under the S0 category of Non-Approved Substances. Any unapproved drug or substance may be considered prohibited by WADA at any time.

Preliminary evidence on TB-500's tissue repair mechanisms has been reviewed in the open literature (see the thymosin beta-4 PubMed indexed work), but research suggests the ergogenic concern, not safety, is what keeps it on the list. Studies have shown the soft-tissue recovery profile is associated with the kind of accelerated return-to-play that meets WADA's "potential to enhance performance" criterion.

Growth hormone secretagogues form the largest banned cluster#

The S2.2 subsection is densely populated with the peptides most commonly marketed to bodybuilders and longevity enthusiasts. S2.2.3 covers growth hormone, its analogues and fragments, including lonapegsomatropin, somapacitan and somatrogon, and growth hormone fragments such as AOD-9604 and hGH 176-191. S2.2.4 captures growth hormone releasing factors including GHRH analogues such as CJC-1293, CJC-1295, sermorelin and tesamorelin, and growth hormone secretagogues and their mimetics .

The S2 list specifically includes CJC-1293, CJC-1295, sermorelin and tesamorelin, anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin, tabimorelin, and the GHRPs . Hexarelin and the GHRP-1 through GHRP-6 series sit alongside them in S2.2 under the GH-releasing peptide cluster.

Detection has tightened. WADA-accredited laboratories screen urine for growth hormone secretagogues including GHRP-2, hexarelin, ipamorelin and CJC-1295, and their metabolites, at sub-nanogram levels. Published detection windows vary by compound, dose and method, so treat any single number you see online with caution: long-acting forms such as CJC-1295 with DAC stay in the body far longer than short-acting GHRPs.

There is no off-season for these compounds. An athlete who uses ipamorelin in November to "support recovery" can still be sanctioned based on a January out-of-competition test, and the resulting ban applies across every sport that signs up to the WADA Code.

GnRH agonists, ACTH, IGF-1, and insulin each have specific rules#

Several peptide categories have nuanced rules worth knowing.

GnRH agonists in males. S2.2.1 prohibits testosterone-stimulating peptides in males including gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues such as buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin . The "in males" qualifier is critical: the ban is sex-specific because the ergogenic mechanism (endogenous testosterone stimulation) is sex-specific.

Corticotrophins. S2.2.2 prohibits corticotrophins and their releasing factors, including corticorelin and tetracosactide . While cortisol is catabolic and not anabolic, ACTH's effects on other adrenal hormones and its use in masking other substances led to its inclusion .

Insulin. All insulins, human, animal, and synthetic analogs, are banned for athletes without a documented diabetes diagnosis. Athletes with type 1 diabetes can obtain a Therapeutic Use Exemption. This is one of the few peptide hormones with a clear, working TUE pathway.

IGF-1. Insulin-like growth factor 1 and its analogues sit in S2 alongside growth hormone fragments. Detection has shifted in part toward biomarker panels rather than direct peptide quantification.

GLP-1 agonists sit on the Monitoring Program, not the Prohibited List#

This is the area with the most active 2026 movement, and the one most likely to be misreported. As of 1 January 2026, semaglutide and tirzepatide are not prohibited. They are being watched.

Tirzepatide (Mounjaro, Zepbound), a dual GIP and GLP-1 receptor agonist, has been added to WADA's 2026 monitoring programme. The programme, effective since 1 January 2026, states that markers of both semaglutide and tirzepatide will be tracked in and out of competition to detect patterns of misuse. GLP-1RAs are used to treat type 2 diabetes but some athletes might seek them out to induce rapid weight loss and alter body composition.

The German anti-doping agency's bulletin on the 2026 list confirms the same: in the 2026 Monitoring Program, the monitoring of semaglutide has been adjusted. From 1 January 2026, markers of semaglutide and additionally of tirzepatide will be monitored to observe possible misuse in-competition and out-of-competition.

What this means practically. The Monitoring Program does not impose sanctions, but data collected may inform future List decisions. A triathlete prescribed semaglutide for clinical obesity is not currently committing an anti-doping rule violation, but research suggests the regulatory trajectory points toward full prohibition. Athletes should expect a TUE process to become harder if and when the move happens. The 2026 monitoring data are precisely what will inform that decision.

Some commentary sources project tighter rules ahead. One industry analysis suggests GLP-1 receptor agonists could move toward full prohibition with therapeutic use exemptions requiring documented failure of two first-line therapies before consideration , though this remains forecasting rather than current WADA policy.

Detection has gotten harder to escape#

The detection landscape changed faster than most athletes realise. Direct peptide quantification, once the only tool, has been supplemented by biomarker panels that track downstream effects long after the parent compound has cleared.

Myostatin inhibitors now face indirect detection via biomarker panels (elevated follistatin combined with suppressed myostatin expression) rather than direct peptide quantification . The same logic is being applied across the growth hormone axis. WADA's GH biomarker test, built on IGF-1 and P-III-NP, is designed to catch growth hormone use after the drug itself has cleared.

The compliance literature, including the BSCG analysis of supplement risks, points out that the supplement market is a vector. Studies have shown that products marketed as legal "recovery aids" frequently contain undeclared peptides. The athlete bears strict liability, and detection in a routine test ends the conversation regardless of intent.

What this means for tested athletes in the US#

Which list applies depends on who tests you, and USADA and the NCAA are the two programs most US athletes meet. Athletes in Olympic and Paralympic sport are tested by USADA under the WADA Code, and the full 2026 Prohibited List applies. College athletes are tested under the NCAA's banned drug classes, a separate list that bans "peptide hormones, growth factors, related substances and mimetics" and names BPC-157, TB-500, MK-677 and IGF-1 among its examples. Professional leagues run their own programs under their collective bargaining agreements, so a league athlete should check that league's policy directly.

A few principles hold up under every audit:

1. If a peptide is sold as a "research chemical" or labelled "not for human use," assume it is in S0.
2. If a peptide affects the growth hormone axis, assume it is in S2.2.
3. If a peptide is a fragment or analogue of an S2 substance, assume the same rules apply by extension.
4. TUE pathways exist for a narrow set of approved peptide medicines (insulin for type 1 diabetes is the cleanest example), not for compounds without regulatory approval.
5. The supplement industry is not your friend here. Third-party certification programs exist for a reason.

For athletes building a protocol around recovery, sleep, or body composition who are also under WADA jurisdiction, the conclusion is straightforward: most of the peptides discussed in wellness communities are off the table. The risk-reward calculation looks very different for a competitive athlete than for an adult outside the testing pool, and that distinction is precisely what makes the doping list worth reading in full.

USADA's Global DRO lets athletes check a named medication, and USADA's TUE Pre-Check Form answers whether an exemption is needed. Klarovel flags every WADA-prohibited peptide with a warning for users who tell us they compete in a drug-tested sport; it does not remove them from view, so the decision stays with the athlete and their anti-doping organisation. See how it works for the methodology, the peptide calculator for dosing reference (research-only), and the disclosures page for our editorial standards.

A clean career is worth more than any peptide#

The peptides on the WADA doping list are there because regulators concluded they meet the criteria for performance enhancement, health risk, or violation of the spirit of sport. For a competitive athlete under WADA, USADA or NCAA testing, the math is simple. A two to four year ban ends most careers. The compounds that get the most attention in wellness marketing, BPC-157, TB-500, the growth hormone secretagogue family, are precisely the ones most likely to trigger that ban. Klarovel flags WADA-prohibited peptides for athletes who tell us they compete in tested sport, so the conflict is visible before anything is started. Register for an account to see those flags on a protocol, or read how the system works before deciding whether it fits your competitive situation.